

# Macrophage Diversity Enhances Tumor Progression and Metastasis

Bin-Zhi Qian<sup>1</sup> and Jeffrey W. Pollard<sup>1,2,3,\*</sup>

<sup>1</sup>Department of Developmental and Molecular Biology

<sup>2</sup>Department of Obstetrics and Gynecology and Women's Health

<sup>3</sup>Cooperative Center for the Study of Reproduction and Infertility Research

Albert Einstein College of Medicine, Bronx, NY 10461, USA

\*Correspondence: jeffrey.pollard@einstein.yu.edu

DOI 10.1016/j.cell.2010.03.014

There is persuasive clinical and experimental evidence that macrophages promote cancer initiation and malignant progression. During tumor initiation, they create an inflammatory environment that is mutagenic and promotes growth. As tumors progress to malignancy, macrophages stimulate angiogenesis, enhance tumor cell migration and invasion, and suppress antitumor immunity. At metastatic sites, macrophages prepare the target tissue for arrival of tumor cells, and then a different subpopulation of macrophages promotes tumor cell extravasation, survival, and subsequent growth. Specialized subpopulations of macrophages may represent important new therapeutic targets.

## Introduction

Tumors have a complex cellular ecology that establishes the malignant potential of the tumor. In these ecosystems, innate immune cells are highly represented, and among the most abundant of these are macrophages. Although the original hypotheses proposed that macrophages are involved in anti-tumor immunity, there is substantial clinical and experimental evidence that in the majority of cases these tumor-associated macrophages (TAMs) enhance tumor progression to malignancy. The tumor-promoting functions of macrophages at the primary site include supporting tumor-associated angiogenesis, promotion of tumor cell invasion, migration, and intravasation, as well as suppression of antitumor immune responses (Condeelis and Pollard, 2006; Pollard, 2004). Macrophages also potentiate the seeding and establishment of metastatic cells and play a role in tumor initiation when inflammation is a causal factor. This review focuses on the diverse roles and functions of macrophages in the primary tumor and at metastatic sites. Accumulating evidence suggests that tumor initiation, progression, and metastasis are affected by dynamic changes in the phenotypes of macrophages and that defined subpopulations of macrophages are responsible for these tumor-promoting activities.

## Macrophage Phenotypes

Macrophages are differentiated cells of the mononuclear phagocytic lineage (Pollard, 2009, and references therein) that are characterized by specific phenotypic characteristics and by the expression of particular markers, none of which are entirely restricted to the lineage (Gordon and Taylor, 2005). In mice, macrophages are phagocytic and express CD11b, F4/80, and colony-stimulating factor-1 receptor (CSF-1R; CD115) and do not express Gr1 (more specifically, Ly6G that is detected by anti-Gr1 antibodies). In humans, phagocytosis, CD68, CD163,

CD16, CD312, and CD115 are the major markers of the lineage. When combined, these characteristics discriminate macrophages from other members of the myeloid lineage such as the polymorphonuclear neutrophils and eosinophils (Joyce and Pollard, 2009).

Macrophage origins, lineage, and regulation by growth factors have been recently reviewed, and attempts have been made to define macrophage subsets (Pollard, 2009, and references therein). The most successful classifications have been applied to subtypes participating in particular immunological responses. These include the "activated" macrophage involved in the responses of type I helper T (Th1) cells to pathogens. This population is activated by interferon gamma and engagement of Toll-like receptors (TLRs) and is characterized by elevated expression of major histocompatibility complex (MHC) class II, expression of interleukin (IL-12) and tumor necrosis factor  $\alpha$  (TNF $\alpha$ ), generation of reactive oxygen species and nitric oxide (NO), and the ability to kill pathogens and cells. In contrast, the "alternatively activated" macrophages that differentiate in response to IL-4 and IL-13 are involved in Th2-type responses, including humoral immunity and wound healing (Gordon, 2003). Another population is the antigen-presenting, migratory dendritic cells that are a branch of the mononuclear phagocytic lineage. There are also other macrophage populations involved in tissue development and homeostasis that are largely regulated by CSF-1 and that do not fall easily into these immunological categories (Pollard, 2009). This argues that there are many populations of macrophages ranging from trophic macrophages involved in developmental processes (often with specialized functions such as the bone-remodeling osteoclast) to those active in tissue repair and the immunological subsets described above (Pollard, 2009). Mantovani and collaborators have suggested that macrophages in tumors are biased away from the activated (M1) to the alternatively acti-

vated type named “M2” (Mantovani and Sica, 2010). Recent gene profiling experiments on TAMs support this shift to an immunoregulatory type (Biswas et al., 2006; Ojalvo et al., 2009; Pucci et al., 2009). However, in contrast to this binary M1/M2 definition, TAMs are composed of several distinct populations that often share features of both types, but with greater overall similarity to macrophages involved in developmental processes (Ojalvo et al., 2009; Ojalvo et al., 2010). The functions of these subpopulations in promoting malignancy are discussed below.

### Macrophages and Cancer

Clinical studies make a strong case that macrophages promote tumorigenesis. In one metaanalysis, it has been reported that over 80% of studies show a correlation between macrophage density and poor patient prognosis (Bingle et al., 2002), and recent studies have further supported this conclusion. For example, there is a strong association between poor survival and increased macrophage density in thyroid, lung, and hepatocellular cancers (Chen et al., 2005; Ryder et al., 2008; Zhu et al., 2008). However, as before there are some exceptions with high macrophage densities correlating with increased survival in pancreatic cancer (Kim et al., 2008). An unbiased transcriptome analysis of follicular lymphoma shows that a macrophage transcriptional signature is a predictor of a poor prognosis, as is increased macrophage density (Farinha et al., 2005). Analysis of the transcriptome of TAMs derived from studies in mouse models of breast cancer has also provided evidence that an enrichment in macrophage transcripts is predictive of poor prognosis and reduced survival in human breast cancer (Ojalvo et al., 2009; Zabuwala et al., 2010).


Macrophage differentiation, growth, and chemotaxis are regulated by several growth factors, including CSF-1, granulocyte-macrophage (GM)-CSF, IL-3, and chemokines such as CCL-2 (Pollard, 2009). Overexpression of CSF-1, the major lineage regulator for macrophages (Pollard, 2009), is associated with poor prognosis in breast, ovarian, endometrial, prostate, hepatocellular, and colorectal cancer, among others (Grobowska et al., 2007; Lin et al., 2002; Mantovani and Sica, 2010; Mroczko et al., 2007; Sapi and Kacinski, 1999; Smith et al., 1995; Zhu et al., 2008). CCL-2 is also overexpressed in a wide range of cancers (Mantovani and Sica, 2010) and is associated with poor prognosis in breast, colorectal, and thyroid cancers (Bailey et al., 2007; Saji et al., 2001; Tanaka et al., 2009; Yoshidome et al., 2009), whereas its absence is associated with increased survival in cervical cancer patients (Zijlmans et al., 2006). In melanoma, there appears to be an inverse relationship between CSF-1 and CCL2 expression, although in this case TAM density still correlates with invasiveness and poor prognosis (Varney et al., 2005). A CSF-1 response transcriptional signature has been found in ductal carcinoma in situ (DCIS) of the breast (Sharma et al., 2009) and in a subset of breast cancers where it correlates with higher tumor grade (Beck et al., 2009). In leiomyosarcomas, the CSF-1 expression signature has been reported as the only independent prognosticator in multivariate analysis (Espinosa et al., 2009). These association studies are highly suggestive of the involvement of these growth factors and chemokines

in tumor macrophage biology. However, a note of caution should be added for this interpretation, given that in some cases tumor cells express the receptors for these growth factors and chemokines and this expression can result in an increased malignant phenotype (Mantovani et al., 2008; Patsialou et al., 2009; Scholl et al., 1994; Smith et al., 1995).

Experimental evidence for the tumor-promoting activation of macrophages has been derived from several different types of experiments. Genetic ablation of the macrophage growth factor CSF-1 in the polyoma middle T (PyMT) oncoprotein mouse model of breast cancer greatly reduces macrophage density in tumors, slows the rate of tumor progression to malignancy, and severely inhibits metastasis (Lin et al., 2001). In these studies, macrophages are the only cells expressing the CSF-1 receptor (CSF-1R). Overexpression of CSF-1 in wild-type tumors results in earlier macrophage recruitment and an accelerated rate of tumor progression and increased metastasis. Genetic ablation of CSF-1 also affects tumor development and reduces malignancy in a genetic model of colon cancer (Oguma et al., 2008) and in an osteosarcoma xenotransplant model (Kubota et al., 2009). Furthermore, genetic ablation in myeloid cells of the *Est-2* transcription factor, a direct effector of the CSF-1 pathway, results in an inhibition of metastasis in both PyMT and orthotopic transplant breast cancer models (Zabuwala et al., 2010).

Similar results have been obtained with therapeutic approaches. Treatment with antisense or antibodies that inhibit CSF-1 or its receptor reduces macrophage recruitment or function in mice bearing xenotransplants of human tumor cells, thereby inhibiting tumor growth and metastasis (Abraham et al., 2010; Aharinejad et al., 2009). Further, specific depletion of macrophages using clodronate-encapsulated liposomes reduces growth in melanoma, ovarian, Lewis lung, teratocarcinoma, rhabdomyosarcoma, and prostate tumor graft models (Gazzaniga et al., 2007; Halin et al., 2009; Kimura et al., 2007; Robinson-Smith et al., 2007; Zeisberger et al., 2006).

It should be recognized, however, that although the experimental and clinical data largely support the hypothesis that macrophages promote malignancy, there are exceptions. For example, in the bone marrow, macrophages play a gatekeeper role by phagocytosing cells that do not express the anti-death receptor CD47. Leukemic cells upregulate this receptor to escape destruction (Jaiswal et al., 2009). Older data also show that liver macrophages (known as Kupffer cells) engulf and kill circulating tumor cells, such that the depletion of Kupffer cells in rats enhances metastasis (Heuff et al., 1993). Further, in peritoneal xenograft experiments in which cancer cells “metastasize” to the liver, depletion of Kupffer cells worsens the prognosis. In addition, these tumors exhibit greater differentiation and less malignancy but grow faster in the absence of macrophages, the mice dying of an increased tumor load (Oosterling et al., 2005). Thus, although these experiments provide further support for a role for macrophages in malignant progression, ironically, the outcome of their depletion was earlier death. These data contrast with the observations that Kupffer cells provide essential mitogens to hepatocellular carcinoma. The mitogen synthesis is due to NF $\kappa$ B signaling in these cells, and ablation of their NF $\kappa$ B signaling results in a reduction in tumor burden (Karin and Greten, 2005).



**Figure 1. Macrophages Promote Tumor Initiation, Progression, and Malignancy**

(A) Chronic smoldering inflammation in response to pathogens or irritants creates a mutagenic and growth-promoting environment in the subepithelial stroma. This environment potentiates the acquisition of oncogenic mutations in the overlying epithelial cells. Central to the inflammatory process are activated macrophages, which are the major producers of reactive oxygen and nitrogen species as well as a wide range of growth factors.

(B) Spontaneous or hereditary mutations cause tumor initiation and progression in cancers not associated with inflammation.

(C) The hyperplastic lesions progress to an intraepithelial neoplasia. This process results in the recruitment of monocytes by chemoattractants from the blood, such as colony stimulating factor-1 (CSF-1) and the chemokine CCL-2. These monocytes differentiate into macrophages in the tumor. These macrophages, unlike those in the initiating inflammatory environment, are not classically activated but instead resemble trophic, immunomodulatory macrophages found during development.

(D) The transition from an intraepithelial neoplasia/adenoma to an early carcinoma is promoted by macrophages in part through their stimulation of the angiogenic switch. Macrophages deliver vascular endothelial growth factor (VEGF) and other angiogenic molecules in a temporal and a spatial fashion to avascular areas, resulting in angiogenesis. In addition, macrophages produce growth factors and proteases that facilitate the escape of tumor cells from their constraining basement membranes. Furthermore, macrophages suppress cytotoxic T cell responses to the invading tumor cells.

(E) After progression to malignancy, and as tumors because late carcinomas, macrophages are continuously recruited through similar mechanisms as before. In the tumor they differentiate into different subpopulations that have functions in: (1) angiogenesis, (2) tumor cell invasion and intravasation, and (3) immunosuppression.

(F) The box in (E) designates an invasive microenvironment as defined in mouse models of breast cancer. In this model, tumor cell motility and invasion (dotted line) are sparked by the production of growth factors/chemokines, such as CXCL12 that binds to its receptor (CXCR4) expressed on both macrophages and tumor cells. Once motility is initiated, it is driven by an obligate epidermal growth factor (EGF)-CSF-1 paracrine loop with macrophages and tumor cells moving in lock step. Invasion also requires matrix formation and destruction through cathepsins and SPARC. Macrophages promote vasculogenesis through angiogenic factors such as VEGF. Tumor cells egress through macrophage clusters on the blood vessels, and thus the macrophages increase both the invasion/intravasation of tumor cells and the number of vascular targets. This allows increased numbers of tumor cells to enter the circulation and thereby enhancement of tumor metastasis.

Although the dynamics within tumors is undoubtedly complex, with macrophages playing both positive and negative roles, the data from animal models as well as from the clinical correlates indicate that in the vast majority of cases macrophages promote tumor progression and metastasis.

### Macrophages in Cancer Initiation and Promotion

There is a growing appreciation that inflammation is the root cause of many cancers. Mantovani and colleagues have called this the seventh hallmark of cancer and reviewed its characteristics as well as the epidemiological and infectious disease literature that supports this hypothesis (Mantovani and Sica, 2010). A causal basis for the role of inflammation in cancer initiation has direct experimental support. In humans, chronic obstructive pulmonary disease is associated with persistent colonization with the bacterium *Haemophilus influenzae* and leads to increased lung cancer risk. In a mouse model of lung cancer, bronchial exposure with *H. influenzae* lysate results in inflammation in the lung and an increase in tumorigenesis (Moghaddam et al., 2009). Myeloid-specific ablation of integrin  $\alpha V$  also results in an ulcerative colitis that induces colonic tumors (Lacy-Hulbert et al., 2007). Ablation in myeloid cells of *Stat3*, a transcription factor whose function suppresses inflammatory responses because it

is a major target of immunosuppressive cytokine IL-10 (Yu et al., 2007), causes inflammation in the colon. This is associated with abundant expression of TNF $\alpha$  and IL-6 by macrophages and results in a chronic colitis and invasive colonic adenocarcinomas (Deng et al., 2010). Similarly, global ablation of IL-10 also results in chronic colitis and intestinal tumors (Yu et al., 2007). Mice that have a genetic ablation of GM-CSF (*Csf2*) and interferon  $\gamma$  (*Ifg*), whose loss would compromise acquired immune responses to pathogens, are found to develop a wide range of cancers (Enzler et al., 2003). The causality of the inflammation in carcinogenesis in these studies comes from experiments in which suppression of the bacterial flora by antibiotic treatment reduces the inflammation and inhibits tumorigenesis (Berg et al., 1996; Deng et al., 2010; Enzler et al., 2003). These data argue that the immune system is normally in balance but that once the negative controls of immune responses are compromised, a persistent inflammatory response to normally commensal organisms results. This inflammation in turn creates a tumor-promoting microenvironment.

The inflammatory state in myeloid cells is controlled by the transcriptional factors NF $\kappa$ B and STAT3 that work in opposition to one another (Karin and Greten, 2005; Yu et al., 2007). NF $\kappa$ B is a central transducer of signals that cause inflammation downstream of TLR activation. Its activity results in expression of inflammatory cytokines such as IL-12 and TNF $\alpha$ , as well as inducible nitric oxide synthase (iNOS) (Karin and Greten, 2005). In the inflammatory responses associated with cancer initiation, NF $\kappa$ B signaling is essential for the inflammatory phenotype (Karin and Greten, 2005). Inhibition of this activity through ablation of I $\kappa$ B kinase  $\alpha$  (IKK $\alpha$ ) in myeloid cells in mouse models of intestinal cancer reduces inflammation and inhibits tumor progression (Greten et al., 2004).

The type of inflammation associated with increased cancer risk because of chronic infection or persistent irritation is often called “smoldering inflammation” (Mantovani and Sica, 2010). This nomenclature is used because the inflammation is low grade without overt clinical consequences. Activated macrophages are central to this type of immune response and work in concert with other immune cells (Balkwill et al., 2005). It has been hypothesized that these immune cells produce a mutagenic environment (Pang et al., 2007) by generating both reactive nitrogen and oxygen species. NO in particular reacts with peroxidates to give nitrosoperoxycarbonate, and this reaction is a major driver of the chemistry of inflammation. This highly reactive compound and other products cause mutations in the adjacent epithelial cells (Meira et al., 2008; Pang et al., 2007). In addition, there is evidence that the inflammatory microenvironment also promotes genetic instability within the developing tumor epithelial cells (Colotta et al., 2009). In either case, the mutations are fixed after replication of the epithelial cells, a process that is stimulated by growth factors synthesized by the infiltrating or resident immune cells that include macrophages. These growth-promoting effects on tumors are caused by the production of IL-6 in hepatocellular carcinoma (HCC) (Lin and Karin, 2007; Naugler et al., 2007) and TNF $\alpha$  (Karin et al., 2006) and IL-6 in colitis associated cancers (Grivnennikov et al., 2009). Interestingly, IL-6 synthesis in Kupffer cells in response to inflammation-induced liver damage is gender dependent with


males who have increased risk of HCC having elevated levels. IL-6 is also required for the increased risk of HCC in female mouse models (Naugler et al., 2007).

Classical models of skin carcinogenesis show that oncogenic mutations caused by low but not initiating doses of carcinogens (such as dimethylbenzanthracene) need to be “fixed” by application of a tumor promoter. The promoter application causes an acute inflammatory response that is dominated by macrophages. TNF $\alpha$  action through NF $\kappa$ B is a causal agent in this promotion through mechanisms that act directly on epithelial cells and on the inflammatory cells in the surrounding stroma, particularly the macrophages (Balkwill, 2009). Similar mechanisms operate in colon cancer (Luo et al., 2004). Together, these data strongly support causal roles for inflammation in cancer initiation and promotion. Although not definitive, given that macrophages have not been uniquely targeted in any system, the data suggest that macrophages are key cells in cancer induced by inflammation.

### Macrophage Functions in the Primary Tumor

The macrophage phenotype associated with cancer initiation and promotion is comparable to the “activated” one (Gordon, 2003). However, once initiated and as the tumors progress toward malignancy, the macrophage phenotype changes from the “inflammatory” type to one that resembles macrophages that promote tissue formation during development (Figure 1) (Pollard, 2004, 2009). In established tumors, NF $\kappa$ B signaling is inhibited by the constitutive expression of p50 homodimers that negatively regulate NF $\kappa$ B and the macrophages display the M2/trophic phenotype with reduced iNOS and TNF $\alpha$  expression (Saccani et al., 2006). Indeed, blocking NF $\kappa$ B function by inhibition of IKK $\alpha$  in cultured macrophages reduces the inflammatory gene expression signature and pushes cells to the trophic/M2 type (Porta et al., 2009). This transition from stimulated to inhibited NF $\kappa$ B function between the initiation and the established tumor stages are poorly understood but appears central to macrophage function in the tumor microenvironment. This alternatively activated/trophic type of macrophage is also found in cancers that arise in the apparent absence of obvious inflammation, such as breast cancer, in which macrophages are recruited to benign tumors in large numbers just as the tumors transition to malignancy (Figure 1).

Macrophage recruitment to tumors has been well-documented in the PyMT mouse model of breast cancer (Lin et al., 2003; Pollard, 2009), where sizeable populations of macrophages are recruited at the adenoma/mammary intraepithelial stage once the tumors have progressed to early malignancy (Lin et al., 2003; Lin et al., 2006; Lin et al., 2001; Wyckoff et al., 2007). Similar patterns also occur in human endometrial and breast cancers (Lewis and Pollard, 2006; Smith et al., 1995). These macrophages are recruited in the presence of CSF-1, which promotes a trophic phenotype, and IL-4 and IL-10, which makes them immunomodulatory (DeNardo et al., 2009; Hamilton, 2008; Lin et al., 2001). Thus, it is a misnomer to consider the leukocytic infiltrate in established tumors to be “inflammatory,” as there are few of the hallmarks of inflammation, such as edema, swelling, and fever.



**Figure 2. Macrophage Phenotypes and Tumorigenesis**

Shown are six macrophage functions that provide extrinsic support to a tumor. Each of these extrinsic activities can be ascribed to a unique macrophage subpopulation. All of these macrophage subtypes are defined by the expression of the canonical markers CD11b, F4/80, and CSF-1R, as well as absence of Gr1 (Ly6G), but they are educated by microenvironmental cues to adopt a particular phenotype and perform the tasks as shown. The population listed as “perivascular” is probably the same as the invasive macrophage population as they have similar activities but they are localized to the abluminal surface of vessels often in cluster. \* designates populations whose transcriptomes have been analyzed.

PyMT tumor cells, CSF-1 is regulated by steroid hormone receptor coactivator-1 (SRC-1), and in SRC-1's absence, although tumor growth is not affected, macrophage recruitment is impaired and tumor cell intravasation and metastasis are inhibited (Wang et al., 2009).

Macrophages have the most complex transcriptome known (Suzuki et al., 2009). Because of their potential diversity of gene products, blood origin, and motile nature, they are ideally suited to perform specific tasks in a timely and spatially appropriate manner. Thus, despite the fact that macrophages have many features in common, distinct tasks appear to require subtypes of macrophages. This is the case in the tumor microenvironment where macrophages are put into service to support the tumor. These protumoral functions of macrophage subpopulations are discussed below and are indicated in Figure 2.

#### **Tumor Cell Invasion, Migration, and Intravasation**

With a combination of intravital imaging and an *in vivo* assay for invasive tumor cells in the PyMT mouse model and in breast cancer cell xenografts, macrophages have been shown to be required for tumor cell migration and invasion (Condeelis and Pollard, 2006). They are the key that unlocks the gate to allow tumor cells to escape. Mechanistically, tumor cells synthesize CSF-1, which stimulates macrophages to move and produce epidermal growth factor (EGF), which in turn activates migration in the tumor cells (Wyckoff et al., 2004) (Figure 1). The macrophages and tumor cells move in lock-step, and inhibition of either the EGF or CSF-1 signaling pathways results in inhibition of migration and chemotaxis of both cell types. This is despite the fact that the CSF-1 receptor and the EGF receptor (ErbB1) are restricted to macrophages and tumor cells, respectively (Wyckoff et al., 2004; Wyckoff et al., 2007). A number of experimental systems provide evidence that macrophages and tumor cells are sufficient for this EGF-CSF-1 paracrine interaction: macrophage-induced migration can be recapitulated with these two cell types in an *in vitro* collagen overlay assay (Condeelis and Pollard, 2006), in mammary epithelial organoid culture system (DeNardo et al., 2009), or in coculture (Green et al., 2009). However, in this latter case, EGF is not involved, whereas CSF-1 is essential. In human breast cancer, EGF expression is restricted to macrophages, whereas CSF-1 is in the tumor cells (Leek et al., 2000; Scholl et al., 1994). In

Macrophage polarization to the invasion-promoting phenotype is in turn regulated by IL-4 synthesized by CD4<sup>+</sup> T cells or tumor cells. In the absence of IL-4, macrophages are unable to promote invasion, and migration of tumor cells and metastasis is dramatically reduced in the PyMT model (DeNardo et al., 2009; Gocheva et al., 2010).

The comigration of macrophages and tumor cells can be initiated by other growth factors such as heregulin and CXCL12 (stromal derived factor-1; SDF-1) dependent on the breast cancer model. However, once initiated, the migration of both cell types still requires paracrine CSF-1-EGF signaling (Hernandez et al., 2009). Given that heregulin and CXCL12 can be synthesized by tumor cells, fibroblasts, or pericytes, these data suggest that a specialized microenvironment is formed that can initiate tumor cell-macrophage invasion (Figure 1). This is consistent with intravital imaging of mammary tumors that shows tumor cell invasion is not uniform but occurs sporadically in particular locations and with observations that tumor cell movement *in vivo* occurs adjacent to macrophages in the PyMT mammary tumor model (Wyckoff et al., 2007) and in xenotransplants on the chick allantoic membrane (Green et al., 2009). Pertinently, CSF-1 expression in human tumors is highest at the invasive edge, a site abundantly populated by macrophages (Lin et al., 2001; Scholl et al., 1994; Smith et al., 1995; Zhu et al., 2008).

Other molecules that may be involved in the macrophage stimulation of invasiveness *in vivo* have also been suggested by tissue culture experiments. For example, Wnt5a acting through the noncanonical pathway (Pukrop et al., 2006) in organoids and TNF $\alpha$  via NF $\kappa$ B in coculture (Hagemann et al., 2005) can promote tumor cell invasion. Further, macrophages have been shown to compensate for the loss of motility in tumor cells after a knockdown of osteopontin (SPP1) (Cheng et al., 2007).

The extracellular matrix plays a major role in modifying tumor cell invasiveness. Macrophages synthesize SPARC/osteonectin (secreted protein, acidic rich in cysteine), which is important

for deposition of collagen IV, enhanced tumor cell invasion, and adhesion to other ECM components (such as fibronectin). SPARC/osteonectin has been shown to be required for spontaneous metastasis from the primary tumor (Sangaletti et al., 2008). Fibrillar Collagen 1 also enhances the invasion process, as tumor cells and macrophages move approximately ten times faster on these structures than through the stroma itself. This has the unfortunate consequence of recruiting cells toward blood vessels given that these collagenous fibrils also anchor these structures (Condeelis and Segall, 2003). At least during development of the mammary gland, macrophages have been shown to promote collagen fibrillogenesis (Ingman et al., 2006). Intravital imaging has shown that intravasation occurs through clusters of macrophages located on the abluminal side of the vessels (Wyckoff et al., 2007). Thus, macrophages on vessels give come-hither signals that result in tumor cell migration down collagen fibrils toward vessels where the tumor cells escape into the vasculature aided by macrophages. This localized movement near to vessels has been confirmed by intravital imaging of xenografted tumors (Gligorijevic et al., 2009). Reduction in the number of tumor-associated macrophages using genetic means (Wyckoff et al., 2007) or inhibition of EGF (DeNardo et al., 2009; Wyckoff et al., 2007) or CSF-1 (Wyckoff et al., 2007) signaling in wild-type mice bearing mammary tumors reduces the numbers of circulating tumor cells. These data suggest that the paracrine loop between the two cell types is required for egress into the circulation in vivo (Wyckoff et al., 2007). Importantly, analysis of clinical material indicates that a structure named the tumor microenvironment of metastasis (TMEM), defined by colocalization of macrophages, tumor cells, and endothelial cells, is a prognostic marker for poor survival in breast cancer (Robinson et al., 2009). These data may also tie together the clinical observations described above, as CSF-1, EGF, CXCR4 are prognostic markers in many cancers.

The macrophages that stimulate tumor cell invasion in vivo have been isolated and their transcriptome interrogated on DNA microarrays. Unsupervised clustering shows this population uniquely separated from a general TAM or a reference population of splenic macrophages. Comparisons with other data sets show that the “invasive macrophages” are most similar to those found during embryogenesis. They are enriched in developmental pathways, in particular the Wnt signaling pathway (Ojalvo et al., 2010). Given that macrophage-produced Wnts promote vascular remodeling in developmental contexts (Lobov et al., 2005), these array data led to the hypothesis that these invasive macrophages link angiogenesis and tumor invasion.

The studies cited above have focused upon invasion and intravasation of single tumor cells typically found in breast cancers. However, there are other types of invasion, including the collective invasion of sheets of cells such as that found in colon cancer. In a mouse model of this disease caused by a mutation in the APC gene and hemizygosity of Smad4, a unique population of immature myeloid cells (which express CD34, CD45, CD11b, and CCR1, but not F4/80) surrounds the invasive front. Depletion of CCL9, the ligand for CCR1, blocks the accumulation of these cells with a consequent inhibition of tumor cell

invasion (Kitamura et al., 2007). These myeloid cells display an unusual phenotype, and, as yet, no complete lineage relationship has been established.

Tumor cell migration also requires proteolytic destruction of the matrix to allow the escape of tumor cells from the confines of the basement membrane. Subsequently, proteolysis is required for tumor cells to migrate through the dense stroma. Macrophages are potent producers of many proteases, including cathepsins, matrix metalloproteinases (MMPs), and serine proteases (Egeblad and Werb, 2002; see Review by K. Kessenbrock et al. on page 52 of this issue). In many tumors, proteases play a role in tumor progression and metastasis (Egeblad and Werb, 2002; Gocheva et al., 2006; Joyce and Pollard, 2009). Depletion of cathepsin B (Gocheva et al., 2010; Vasiljeva et al., 2006) and S (Gocheva et al., 2010) from macrophages results in reduced tumor cell invasion and inhibition of metastasis in the PyMT model. Urokinase/Plasminogen activator (uPA) is mostly produced by macrophages, and in the PyMT model its loss also inhibits metastasis (Almholt et al., 2005). In the colon model of collective cell migration described above, the immature myeloid cells produce both MMP9 and MMP2 that are required for the tumor cell invasion (Kitamura et al., 2007).

### Angiogenesis

In most tumors, there is a dramatic enhancement of vascular density from the benign-to-malignant transition, a process referred to as the angiogenic switch (Hanahan et al., 1996). The formation of a complete vasculature is a complex process with many cell types, often with overlapping functions influencing its outcome in tumors. Cells of the mononuclear phagocytic lineage cells, and macrophages in particular, are major contributors to this process (Zumsteg and Christofori, 2009). Studies in which macrophages are reduced in mammary tumors using the null mutation in the *Csf1* gene show that these cells are required for the angiogenic switch. This effect is reversed by the re-expression of CSF-1 in the mammary epithelium (Lin et al., 2006). Overexpression of CSF-1 in wild-type mice results in the premature accumulation of macrophages into hyperplastic lesions and a dramatic early angiogenic switch that in turn accelerates the transition to malignancy. These data strongly argue for the role of the angiogenic switch in regulating the malignant transition and for macrophages to be important players in this regulation (Lin and Pollard, 2007). These studies also show that macrophages play a significant role in vascular remodeling as tumors progress to late carcinoma stages (Lin et al., 2006). A similar macrophage depletion strategy also reduces angiogenesis in an osteosarcoma model (Kubota et al., 2009). Further, most TAM depletion strategies using liposome-encapsulated clodronate, described above, inhibit angiogenesis in transplanted tumor models (Gazzaniga et al., 2007; Halin et al., 2009; Kimura et al., 2007; Zeisberger et al., 2006). This effect seems to be the most likely cause of reduced tumor growth after macrophage depletion seen in these transplants models, as their growth is very dependent upon rapid angiogenesis.

A subpopulation of CD11b-positive myeloid cells characterized by expression of Tie2, a marker of mature endothelial cells, has been described in tumors. These myeloid cells appear to be derived from Tie2-expressing monocytes that are found

in human cancer patients and in mice (Murdoch et al., 2008). Coinjection of tumor cells with these cells enhances angiogenesis. In contrast, ablation of these cells impairs angiogenesis in several mouse models of cancer (De Palma et al., 2005). Transcriptional profiling of Tie2-positive and -negative monocytes shows that they are distinct classes, although highly related (Pucci et al., 2009). We have also identified two subpopulations of macrophages in the PyMT model that express differing levels of Tie2 (data not shown). They are probably equivalent to the two populations described by Pucci et al. (2009), who defined their populations by a reporter gene assay rather than the more sensitive analysis of cell surface markers by fluorescence-activated cell sorting. Indeed, *Tie2* messenger RNA (mRNA) is expressed in the Tie2-negative population albeit at a 20-fold lower level than the expression in the Tie2-positive population (Pucci et al., 2009).

Transcriptional profiling on high-density oligonucleotide arrays of these TAMs shows that they are highly enriched in transcripts that encode angiogenic molecules (Ojalvo et al., 2009). Reinforcing this result, in the PyMT mammary cancer model, gene ablation of the *Ets2* transcription factor in the myeloid lineage inhibits angiogenesis. Transcriptional profiling of the *Ets2*-deficient TAMs shows that ETS2 controls the expression of transcripts encoding proteins that regulate angiogenesis (Zabuawala et al., 2010). In both cases, comparisons of TAM transcriptomes with available clinical databases shows that these transcriptional signatures are predictive of survival (Ojalvo et al., 2009; Zabuawala et al., 2010). These data make a strong case that this population of TAMs plays important roles in tumor progression through their effects on angiogenesis. Moreover, the proangiogenic role of TAMs in mouse models is consistent with clinical observations in breast cancer that correlate macrophage density with increased microvessel density and poor prognosis (Leek and Harris, 2002).

Hypoxia is a major driver of angiogenesis. Macrophages accumulate in hypoxic areas of the tumor and are particularly associated with necrotic tissue (Murdoch et al., 2008). HIF1 $\alpha$ , whose expression is constitutive in macrophages, modulates the recruitment of macrophages to hypoxic regions of the tumor. This recruitment is through chemokines, especially CCL-2 and endothelins (Grimshaw et al., 2002; Murdoch et al., 2008). At the hypoxic site, HIF1 $\alpha$  regulates the transcription of a large panel of genes associated with angiogenesis, including *VEGF* (Lewis and Hughes, 2007; Murdoch et al., 2008). These genes then mediate the revascularization of the necrotic zones (Murdoch et al., 2008). This process can be modeled in *in vivo* angiogenesis models such as in T47D tumor cell spheroids (Murdoch et al., 2008) or in transplant tumor models (Zumsteg and Christofori, 2009).

Macrophages produce VEGF in both human and mouse mammary tumors (Leek and Harris, 2002; Lin et al., 2006). VEGF overexpression in macrophage-depleted mice increases vascularization and also accelerates the transition to malignancy (Lin et al., 2007). This rescue is also associated with the recruitment of macrophages even in the absence of CSF-1, and these cells and their angiogenesis-regulating gene products may be partially responsible for the angiogenic response. Targeted ablation of the *Vegfa* gene in myeloid cells results

in the inhibition of the angiogenic switch (Stockmann et al., 2008). However, despite the failure of the angiogenic switch, the tumors that grow out are more aggressive and are characterized by a less dense but more coherent vasculature. This aggressive growth suggests strong selection in response to hypoxic stress for tumor cells that are able to use glycolysis as a source for energy (Stockmann et al., 2008).

Macrophages can produce VEGF, but in other cases they also make it bioavailable through the production of MMP9, which releases VEGF from extracellular depots. Targeting of macrophages with bisphosphonate in a model of cervical carcinogenesis inhibits angiogenesis because macrophages are the major producers of MMP9 in this model and are recruited by CCL2 (Giraudo et al., 2004). Lack of CCL2 signaling reduces macrophage infiltration but has only a modest effect on tumor progression because of a compensatory recruitment of MMP9-producing neutrophils (Pahler et al., 2008). However, in other reports CCL2 recruitment of macrophages is required for angiogenesis (Fujimoto et al., 2009; Gazzaniga et al., 2007). In a glioblastoma mouse model, stromal-synthesized SDF-1 (CXCL12) recruits a myeloid cell population that expresses MMP9 and releases matrix-bound VEGF. This VEGF stimulates not only angiogenesis but also tumor cell invasion (Du et al., 2008).

### Immunoregulation

Macrophages are central to many immune responses and are clearly immunoregulatory cells within the tumor. In some cases, this can result in rejection, as both macrophages and dendritic cells are able to present antigens to cytotoxic T cells and macrophages are adept at tumor killing. Pioneering work from Fidler and colleagues indicated that activated macrophages can kill tumor cells and eliminate metastases (Fidler and Schroit, 1988). Similarly, inhibition of tumor growth in xenograft models have recently been obtained by activating macrophages by either overexpressing GM-CSF (Eubank et al., 2009) or treating tumors with CpG together with anti-IL10 (Guiducci et al., 2005). These latter treatments activate Toll-like receptors and block immunosuppression, respectively. However, in the vast majority of tumors, there does not appear to be substantial immunological limitation of tumor growth. This suggests that the tumor microenvironment suppresses any immune response and alters the phenotype to one that promotes the tumor (Swann et al., 2008). The exact role of macrophages or their cousins in this process has not been fully delineated. Phenotyping of the transcriptome of TAMs has suggested that they represent an immunological regulatory type. This is characterized by downregulation of transcripts involved with immunological activation such as IL-12, IL-18, and the TLR signaling pathway and upregulation of transcripts found in alternatively activated macrophages such as arginase (Biswas et al., 2006; Ojalvo et al., 2009). Importantly in the PyMT model this polarization of macrophages is caused by IL-4 synthesized by CD4-positive T cells (DeNardo et al., 2009). Furthermore, macrophages in tumors develop in high concentrations of CSF-1 that support their differentiation to trophic macrophages and away from immunologically activated ones, which are controlled by GM-CSF (Hamilton, 2008; Mantovani and Sica, 2010).

Macrophages can inhibit cytotoxic T cell responses through several mechanisms. For example, macrophages produce IL-10 that in turn induces monocytes to express the costimulatory molecule programmed death ligand (PD)-L1 and suppresses cytotoxic T cell responses (Kuang et al., 2009). Macrophages in human ovarian cancers produce CCL22, a chemokine that regulates the influx of regulatory T cells ( $T_{reg}$ ) that suppress cytotoxic T cell responses. The abundance of these  $T_{reg}$  in ovarian cancer predicts poor survival (Curiel et al., 2004). In mammary tumor xenografts, a newly recruited macrophage population suppressed immune responses through synthesis of PGE2 and TGF- $\beta$  (Torroella-Kouri et al., 2009).

Myeloid-derived suppressor cells (MDSCs) are another immunosuppressive immune cell population related to macrophages that has come to the forefront in recent years. MDSCs are a mixed population of myeloid cells that accumulate in pathological conditions including cancer. Morphologically, these populations consist of monocytes, granulocytes, and immature myeloid cells and are identified by their capacity to suppress cytotoxic T cell responses (Gabrilovich and Nagaraj, 2009). In mice, MDSCs express both the myeloid cell marker CD11b and the granulocyte marker Gr1. The presence of these markers satisfies the classical definition of neutrophils, and therefore MDSCs are not mononuclear phagocytes (Gabrilovich and Nagaraj, 2009). This cell surface marker analysis has also been reinforced by gene expression analysis that shows that MDSCs are markedly different from TAMs (Pucci et al., 2009). However, a key question remains whether these cells can differentiate solely into mature granulocytes or whether they can become macrophages *in vivo* and whether there are other more myeloid subpopulations of these cells.

### Macrophages at the Metastatic Site

Most studies have focused upon events occurring in the primary tumor, often with metastasis as an end point. However, metastasis requires not only the release of cells from the primary site but also their transit through the circulation or lymphatics to arrive at a distant site where the cells need to extravasate, survive, and prosper. This process of metastasis is very inefficient. In humans, there are many thousands of circulating cells released by tumors every day, but only a few successfully make metastases. In fact, the most likely fate for these cells is death, with extravasation and establishment of micrometastases being major rate-limiting events (Joyce and Pollard, 2009). Although it has long been known that macrophages populate metastatic lesions (Joyce and Pollard, 2009), only recently has their role in metastasis been appreciated.

Cancer is a systemic disease, and primary tumors secrete factors that influence metastatic outcome at distant sites. For example, the tumor-derived extracellular matrix protein, versican, stimulates metastasis in the Lewis lung carcinoma model through TLR2 signaling in myeloid cells (Kim et al., 2009). Aggressive tumors systemically influence less aggressive indolent ones to grow faster and to stimulate the growth of micrometastases through the acquisition of bone marrow-derived cells. In these studies, osteopontin expressed from the aggressive tumor has been shown to be necessary but not sufficient for the mobilization of bone marrow cells (McAllister

et al., 2008). In neither study was the phenotype of the bone marrow cells that influence the metastatic site fully characterized; however, it is likely that macrophages are major players in these responses.

Primary tumors have also been shown to cause the accumulation myeloid derived cells at distant sites, and this process enhances metastatic efficiency (Kaplan et al., 2005). These primed sites are termed the premetastatic niche. Their location can be altered, for example from lung to bone, by serum conditioned by the primary tumor giving organ specificity to the metastases (Kaplan et al., 2005). Among the tumor-produced factors required for the premetastatic niche are the myeloid chemoattractants S100A8 and A9, whose synthesis is induced by the primary tumor. S100 proteins induce the synthesis of amyloid protein A that signals through TLR4 in myeloid and endothelial cells (Hiratsuka et al., 2006; Hiratsuka et al., 2008). In addition, lysyl oxidase crosslinks the collagen at the premetastatic site and is essential for the myeloid recruitment (Erler et al., 2009). These myeloid cells secrete MMP9 that releases matrix-bound VEGF, whose function is in turn required for the increase in metastatic efficiency (Hiratsuka et al., 2002). Although the myeloid cells that accumulate in these niches have not been fully characterized, they are CD11b- and VEGFR1-positive, characteristics of mononuclear phagocytic cells (Hiratsuka et al., 2006; Kaplan et al., 2005). Inhibition of VEGFR1 signaling by antibody inhibition or receptor mutation also inhibits the formation of the premetastatic niche (Hiratsuka et al., 2002; Kaplan et al., 2005). However, there is a contradictory report challenging these findings, albeit in a different model of metastasis (Dawson et al., 2009). It has been proposed that these niches provide sites for tumor cells to adhere and prosper (Psaila and Lyden, 2009). Alternatively, these niches might simply prepare the tissue for successful colonization by being a reservoir of monocytes that can be rapidly mobilized to differentiate into macrophages in response to incoming tumor cells, a process that enhances metastatic seeding and growth (Qian et al., 2009).

Metastatic cells can colonize and grow in particular tissues even in the absence of a primary tumor (Joyce and Pollard, 2009). Recent *ex vivo* imaging studies of lungs indicate that macrophages are recruited to these extravasating tumor cells and ablation of these macrophages dramatically reduce the extravasation efficiency and the subsequent tumor cell survival such that metastatic cell seeding efficiency is markedly reduced (Qian et al., 2009). Furthermore, ablation of these recruited macrophages limits subsequent metastatic growth, even after metastatic lesions had been established. These effects were accompanied by physical interactions between macrophages and metastatic tumor cells, suggesting short-range transmission of growth and survival signals (Qian et al., 2009). Phenotyping revealed that the metastasis-associated macrophages differ from the CD11c-positive lung interstitial resident macrophages. Instead, they are regulated by CSF-1 and characterized by cell surface expression of CD11b, F4/80, VEGFR1, and CCR2 and the absence of Gr1 and low CD11c (Qian et al., 2009). Thus, this prometastatic macrophage is another population with a distinct phenotype (Figure 2) that is found not only in these experimental models but also in metastases derived from autochthonous (spontaneous and native) models (Qian et al., 2009).


In summary, mononuclear phagocytes appear not only to set up preferred sites for metastatic cell seeding but also to enhance tumor cell extravasation, establishment, and subsequent growth of metastatic lesions (Figure 3).

### Perspectives

Malignant cells can be reverted to a quiescent differentiated state by incorporation into an embryonic microenvironment (Joyce and Pollard, 2009). This indicates the microenvironment is dominant over malignancy. Thus, for tumors to progress and become malignant they must manipulate their microenvironment to one that is at least permissive if not promoting. This is probably due to selection of oncogenic mutations that lead to secretion of molecules that alter the cellular composition and function of the microenvironment. Among these changes is the recruitment of bone marrow-derived cells, of which macrophages are particularly abundant. Macrophages in primary and secondary tumors confer several properties that enhance progression and metastasis. Each function is affected by a particular macrophage subpopulation (Figure 2). Elsewhere, we have reviewed data that macrophages play important trophic roles during development and have argued that these roles are recapitulated in tumors (Pollard, 2009). This conjecture is supported by transcriptome analysis on high-density arrays that show the TAMs are most similar to macrophages involved in developmental processes (Ojalvo et al., 2009). These trophic macrophages are also characterized as immunomodulatory as would be expected for cells involved in normal processes. However, in contrast to developing systems, tumors have lost their “off” switches because of oncogenic mutations, thus losing control of positional identity. Consequently, tumors continue to inappropriately call for trophic support from macrophages. This leads to macrophage enhancement of malignancy at every step of the way.

Undoubtedly, as we dig deeper many other macrophage subpopulations will be revealed. For example, macrophages in prostate cancer cause the tumor cells to become resistant to the inhibitory effects of therapeutic androgen receptor antagonists, and instead these drugs become agonists for growth. This resistance is mediated by transcriptional cofactor TAB2, which acts as a sensor of inflammation in the form of IL-1 $\beta$  and whose phosphorylation causes release of gene transcription that is normally repressed by the antiandrogen. Similar mechanisms operate with antiestrogens in MCF-7 breast cancer cells (Zhu et al., 2006). Macrophages might therefore have a further protumor function in the progression of sex steroid hormone-dependent cancers to steroid independence.

Many experimental challenges remain. For example, caution needs to be exercised in the interpretation of experiments involving tumor transplantation, often into immunocompetent animals. These experiments are confounded by antigraft reactions even in syngeneic contexts, as well as the skewed immune reactions in immunocompromised mice. They cannot represent the subtlety of immune cell interactions that occurs during the progression of autochthonous tumors. Thus, for macrophage biology, immune-competent animals need to be used, and although valuable results can be obtained from transplant experiments, the conclusions need to be validated in



**Figure 3. Macrophages Promote Seeding and Growth of Metastatic Cells**

Myeloid cells, most likely macrophages, are recruited to the premetastatic niche in response to secreted products from the primary tumor. The metastatic target organs contain fibroblasts and elaborate extracellular matrix consisting of fibronectin and collagen. These niches direct and enhance tumor cell seeding in sites distant from the primary tumor. Once the tumor cells arrive at the metastatic site and begin to extravasate, they recruit macrophages that are differentiated from blood borne monocytes. These macrophages enhance the ability of tumor cells to extravasate and promote their subsequent survival and growth. They continue to accumulate in metastatic lesions, where they stimulate the growth and survival of the metastatic cells. Several growth factors and signaling pathways are important for these macrophage functions, including vascular endothelial growth factor (VEGFR) in the premetastatic site and colony stimulating factor-1 (CSF-1).

models of spontaneously arising tumors. Another challenge is to confirm that the macrophage subtypes and functions found in rodents are present in human tumors. It is likely that comparable macrophage populations exist given that the individual TAM expression signatures derived from mice are represented in human tumor datasets and can even be predictive (Ojalvo et al., 2009; Zabuawala et al., 2010). Yet, this validation of the rodent data in humans is essential before antimacrophage therapeutics are designed.

The evidence that macrophages provide trophic support to tumors and the genetic experiments that show that if you remove this support malignancy is suppressed strongly argue that these cells or their unique signaling pathways are therapeutic targets. Unlike tumor cells, the genomes of macrophages are stable, suggesting that they may not as readily become drug resistant. Significant progress has been made in identifying the molecular basis for both macrophage phenotypes and their actions in promoting specific aspects of tumor behavior. Some important signaling pathways have been defined as described above, including those in response to VEGFa, TNF $\alpha$ , EGF, and CSF-1. In addition, some transcriptional regulators (NF $\kappa$ B, STAT3) that bias macrophage phenotypes from pro- to

antitumoral and molecules that recruit these cells to tumors such as CCL-2 have been identified. Panmacrophage inhibitors such as drugs that inhibit CSF-1 signaling are in early clinical trials. However, in the future there may also be targeted therapies that uniquely strike macrophages in the tumor microenvironment and macrophage therapeutics that enhance the activities of conventional treatments.

#### ACKNOWLEDGMENTS

This work was supported by grants from the National Institutes of Health to J.W.P. (NIH PO1 CA100324, U01CA143233, and RO1 CA131270) and Albert Einstein Cancer Center Core grant P30 CA 13330. J.W.P. is the Louis Goldstein Swan Chair in Women's Cancer Research.

#### REFERENCES

- Abraham, D., Zins, K., Sioud, M., Lucas, T., Schäfer, R., Stanley, E.R., and Aharinejad, S. (2010). Stromal cell-derived CSF-1 blockade prolongs xenograft survival of CSF-1-negative neuroblastoma. *Int. J. Cancer* *126*, 1339–1352.
- Aharinejad, S., Sioud, M., Lucas, T., and Abraham, D. (2009). Targeting stromal-cancer cell interactions with siRNAs. *Methods Mol. Biol.* *487*, 243–266.
- Almholt, K., Lund, L.R., Rygaard, J., Nielsen, B.S., Danø, K., Rømer, J., and Johnsen, M. (2005). Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. *Int. J. Cancer* *113*, 525–532.
- Bailey, C., Negus, R., Morris, A., Ziprin, P., Goldin, R., Allavena, P., Peck, D., and Darzi, A. (2007). Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer. *Clin. Exp. Metastasis* *24*, 121–130.
- Balkwill, F. (2009). Tumour necrosis factor and cancer. *Nat. Rev. Cancer* *9*, 361–371.
- Balkwill, F., Charles, K.A., and Mantovani, A. (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. *Cancer Cell* *7*, 211–217.
- Beck, A.H., Espinosa, I., Edris, B., Li, R., Montgomery, K., Zhu, S., Varma, S., Marinelli, R.J., van de Rijn, M., and West, R.B. (2009). The macrophage colony-stimulating factor 1 response signature in breast carcinoma. *Clin. Cancer Res.* *15*, 778–787.
- Berg, D.J., Davidson, N., Kühn, R., Müller, W., Menon, S., Holland, G., Thompson-Snipes, L., Leach, M.W., and Rennick, D. (1996). Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. *J. Clin. Invest.* *98*, 1010–1020.
- Bingle, L., Brown, N.J., and Lewis, C.E. (2002). The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. *J. Pathol.* *196*, 254–265.
- Biswas, S.K., Gangi, L., Paul, S., Schioppa, T., Saccani, A., Sironi, M., Bottazzi, B., Doni, A., Vincenzo, B., Pasqualini, F., et al. (2006). A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF- $\kappa$ B and enhanced IRF-3/STAT1 activation). *Blood* *107*, 2112–2122.
- Chen, J.J., Lin, Y.C., Yao, P.L., Yuan, A., Chen, H.Y., Shun, C.T., Tsai, M.F., Chen, C.H., and Yang, P.C. (2005). Tumor-associated macrophages: the double-edged sword in cancer progression. *J. Clin. Oncol.* *23*, 953–964.
- Cheng, J., Huo, D.H., Kuang, D.M., Yang, J., Zheng, L., and Zhuang, S.M. (2007). Human macrophages promote the motility and invasiveness of osteopontin-knockdown tumor cells. *Cancer Res.* *67*, 5141–5147.
- Colotta, F., Allavena, P., Sica, A., Garlanda, C., and Mantovani, A. (2009). Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. *Carcinogenesis* *30*, 1073–1081.
- Condeelis, J., and Pollard, J.W. (2006). Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. *Cell* *124*, 263–266.
- Condeelis, J., and Segall, J.E. (2003). Intravital imaging of cell movement in tumours. *Nat. Rev. Cancer* *3*, 921–930.
- Curiel, T.J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J.R., Zhang, L., Burow, M., et al. (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. *Nat. Med.* *10*, 942–949.
- Dawson, M.R., Duda, D.G., Chae, S.S., Fukumura, D., and Jain, R.K. (2009). VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation. *PLoS ONE* *4*, e6525.
- De Palma, M., Venneri, M.A., Galli, R., Sergi Sergi, L., Politi, L.S., Sampaolosi, M., and Naldini, L. (2005). Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. *Cancer Cell* *8*, 211–226.
- DeNardo, D.G., Barreto, J.B., Andreu, P., Vasquez, L., Tawfik, D., Kolhatkar, N., and Coussens, L.M. (2009). CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. *Cancer Cell* *16*, 91–102.
- Deng, L., Zhou, J.F., Sellers, R.S., Li, J.F., Nguyen, A.V., Wang, Y., Orlofsky, A., Liu, Q., Hume, D.A., Pollard, J.W., et al. (2010). A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis. *Am. J. Pathol.* *176*, 952–967.
- Du, R., Lu, K.V., Petritsch, C., Liu, P., Ganss, R., Passegué, E., Song, H., Vandenberg, S., Johnson, R.S., Werb, Z., and Bergers, G. (2008). HIF1 $\alpha$  induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. *Cancer Cell* *13*, 206–220.
- Egeblad, M., and Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. *Nat. Rev. Cancer* *2*, 161–174.
- Enzler, T., Gillissen, S., Manis, J.P., Ferguson, D., Fleming, J., Alt, F.W., Mihm, M., and Dranoff, G. (2003). Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. *J. Exp. Med.* *197*, 1213–1219.
- Erler, J.T., Bennewith, K.L., Cox, T.R., Lang, G., Bird, D., Koong, A., Le, Q.T., and Giaccia, A.J. (2009). Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. *Cancer Cell* *15*, 35–44.
- Espinosa, I., Beck, A.H., Lee, C.H., Zhu, S., Montgomery, K.D., Marinelli, R.J., Ganjoo, K.N., Nielsen, T.O., Gilks, C.B., West, R.B., and van de Rijn, M. (2009). Coordinate expression of colony-stimulating factor-1 and colony-stimulating factor-1-related proteins is associated with poor prognosis in gynecological and nongynecological leiomyosarcoma. *Am. J. Pathol.* *174*, 2347–2356.
- Eubank, T.D., Roberts, R.D., Khan, M., Curry, J.M., Nuovo, G.J., Kuppusamy, P., and Marsh, C.B. (2009). Granulocyte macrophage colony-stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages. *Cancer Res.* *69*, 2133–2140.
- Farinha, P., Masoudi, H., Skinnider, B.F., Shumansky, K., Spinelli, J.J., Gill, K., Klasa, R., Voss, N., Connors, J.M., and Gascoyne, R.D. (2005). Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). *Blood* *106*, 2169–2174.
- Fidler, I.J., and Schroit, A.J. (1988). Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. *Biochim. Biophys. Acta* *948*, 151–173.
- Fujimoto, H., Sangai, T., Ishii, G., Ikehara, A., Nagashima, T., Miyazaki, M., and Ochiai, A. (2009). Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. *Int. J. Cancer* *125*, 1276–1284.
- Gabrilovich, D.I., and Nagaraj, S. (2009). Myeloid-derived suppressor cells as regulators of the immune system. *Nat. Rev. Immunol.* *9*, 162–174.
- Gazzaniga, S., Bravo, A.I., Guglielmotti, A., van Rooijen, N., Maschi, F., Vecchi, A., Mantovani, A., Mordoh, J., and Wainstok, R. (2007). Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and

- tumor growth in a human melanoma xenograft. *J. Invest. Dermatol.* *127*, 2031–2041.
- Giraudo, E., Inoue, M., and Hanahan, D. (2004). An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. *J. Clin. Invest.* *114*, 623–633.
- Glgorijevic, B., Kedrin, D., Segall, J.E., Condeelis, J., and van Rheenen, J. (2009). Dendra2 photoswitching through the Mammary Imaging Window. *J. Vis. Exp.* 10.3791/1278.
- Gocheva, V., Zeng, W., Ke, D., Klimstra, D., Reinheckel, T., Peters, C., Hanahan, D., and Joyce, J.A. (2006). Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. *Genes Dev.* *20*, 543–556.
- Gocheva, V., Wang, H.W., Gadea, B.B., Shree, T., Hunter, K.E., Garfall, A.L., Berman, T., and Joyce, J.A. (2010). IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. *Genes Dev.* *24*, 241–255.
- Gordon, S. (2003). Alternative activation of macrophages. *Nat. Rev. Immunol.* *3*, 23–35.
- Gordon, S., and Taylor, P.R. (2005). Monocyte and macrophage heterogeneity. *Nat. Rev. Immunol.* *5*, 953–964.
- Green, C.E., Liu, T., Montel, V., Hsiao, G., Lester, R.D., Subramaniam, S., Goniias, S.L., and Klemke, R.L. (2009). Chemoattractant signaling between tumor cells and macrophages regulates cancer cell migration, metastasis and neovascularization. *PLoS ONE* *4*, e6713.
- Greten, F.R., Eckmann, L., Greten, T.F., Park, J.M., Li, Z.W., Egan, L.J., Kagannoff, M.F., and Karin, M. (2004). IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. *Cell* *118*, 285–296.
- Grimshaw, M.J., Wilson, J.L., and Balkwill, F.R. (2002). Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumors. *Eur. J. Immunol.* *32*, 2393–2400.
- Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., and Karin, M. (2009). IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. *Cancer Cell* *15*, 103–113.
- Groblewska, M., Mroczko, B., Wereszczy ska-Siemiakowska, U., My liwiec, P., Kedra, B., and Szmitskowski, M. (2007). Serum levels of granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF) in pancreatic cancer patients. *Clin. Chem. Lab. Med.* *45*, 30–34.
- Guiducci, C., Vicari, A.P., Sangaletti, S., Trinchieri, G., and Colombo, M.P. (2005). Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. *Cancer Res.* *65*, 3437–3446.
- Hagemann, T., Wilson, J., Kulbe, H., Li, N.F., Leinster, D.A., Charles, K., Klemm, F., Pukrop, T., Binder, C., and Balkwill, F.R. (2005). Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. *J. Immunol.* *175*, 1197–1205.
- Halin, S., Rudolfsson, S.H., Van Rooijen, N., and Bergh, A. (2009). Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model. *Neoplasia* *11*, 177–186.
- Hamilton, J.A. (2008). Colony-stimulating factors in inflammation and autoimmunity. *Nat. Rev. Immunol.* *8*, 533–544.
- Hanahan, D., Christofori, G., Naik, P., and Arbeit, J. (1996). Transgenic mouse models of tumor angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. *Eur. J. Cancer* *32A*, 2386–2393.
- Hernandez, L., Smirnova, T., Kedrin, D., Wyckoff, J., Zhu, L., Stanley, E.R., Cox, D., Muller, W.J., Pollard, J.W., Van Rooijen, N., and Segall, J.E. (2009). The EGF/CSF-1 paracrine invasion loop can be triggered by heregulin beta1 and CXCL12. *Cancer Res.* *69*, 3221–3227.
- Heuff, G., Oldenburg, H.S., Boutkan, H., Visser, J.J., Beelen, R.H., Van Rooijen, N., Dijkstra, C.D., and Meyer, S. (1993). Enhanced tumour growth in the rat liver after selective elimination of Kupffer cells. *Cancer Immunol. Immunother.* *37*, 125–130.
- Hiratsuka, S., Nakamura, K., Iwai, S., Murakami, M., Itoh, T., Kijima, H., Shipley, J.M., Senior, R.M., and Shibuya, M. (2002). MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. *Cancer Cell* *2*, 289–300.
- Hiratsuka, S., Watanabe, A., Aburatani, H., and Maru, Y. (2006). Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. *Nat. Cell Biol.* *8*, 1369–1375.
- Hiratsuka, S., Watanabe, A., Sakurai, Y., Akashi-Takamura, S., Ishibashi, S., Miyake, K., Shibuya, M., Akira, S., Aburatani, H., and Maru, Y. (2008). The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. *Nat. Cell Biol.* *10*, 1349–1355.
- Ingman, W.V., Wyckoff, J., Gouon-Evans, V., Condeelis, J., and Pollard, J.W. (2006). Macrophages promote collagen fibrillogenesis around terminal end buds of the developing mammary gland. *Dev. Dyn.* *235*, 3222–3229.
- Jaiswal, S., Jamieson, C.H., Pang, W.W., Park, C.Y., Chao, M.P., Majeti, R., Traver, D., van Rooijen, N., and Weissman, I.L. (2009). CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. *Cell* *138*, 271–285.
- Joyce, J.A., and Pollard, J.W. (2009). Microenvironmental regulation of metastasis. *Nat. Rev. Cancer* *9*, 239–252.
- Kaplan, R.N., Riba, R.D., Zacharoulis, S., Bramley, A.H., Vincent, L., Costa, C., MacDonald, D.D., Jin, D.K., Shido, K., Kerns, S.A., et al. (2005). VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. *Nature* *438*, 820–827.
- Karin, M., and Greten, F.R. (2005). NF-kappaB: linking inflammation and immunity to cancer development and progression. *Nat. Rev. Immunol.* *5*, 749–759.
- Karin, M., Lawrence, T., and Nizet, V. (2006). Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. *Cell* *124*, 823–835.
- Kim, D.W., Min, H.S., Lee, K.H., Kim, Y.J., Oh, D.Y., Jeon, Y.K., Lee, S.H., Im, S.A., Chung, D.H., Kim, Y.T., et al. (2008). High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer. *Br. J. Cancer* *98*, 1118–1124.
- Kim, S., Takahashi, H., Lin, W.W., Descargues, P., Grivennikov, S., Kim, Y., Luo, J.L., and Karin, M. (2009). Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. *Nature* *457*, 102–106.
- Kimura, Y.N., Watari, K., Fotovati, A., Hosoi, F., Yasumoto, K., Izumi, H., Kohno, K., Umezawa, K., Iguchi, H., Shirouzu, K., et al. (2007). Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis. *Cancer Sci.* *98*, 2009–2018.
- Kitamura, T., Kometani, K., Hashida, H., Matsunaga, A., Miyoshi, H., Hosogi, H., Aoki, M., Oshima, M., Hattori, M., Takabayashi, A., et al. (2007). SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion. *Nat. Genet.* *39*, 467–475.
- Kuang, D.M., Zhao, Q., Peng, C., Xu, J., Zhang, J.P., Wu, C., and Zheng, L. (2009). Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. *J. Exp. Med.* *206*, 1327–1337.
- Kubota, Y., Takubo, K., Shimizu, T., Ohno, H., Kishi, K., Shibuya, M., Saya, H., and Suda, T. (2009). M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. *J. Exp. Med.* *206*, 1089–1102.
- Lacy-Hulbert, A., Smith, A.M., Tissire, H., Barry, M., Crowley, D., Bronson, R.T., Roes, J.T., Savill, J.S., and Hynes, R.O. (2007). Ulcerative colitis and autoimmunity induced by loss of myeloid alphaV integrins. *Proc. Natl. Acad. Sci. USA* *104*, 15823–15828.
- Leek, R.D., and Harris, A.L. (2002). Tumor-associated macrophages in breast cancer. *J. Mammary Gland Biol. Neoplasia* *7*, 177–189.
- Leek, R.D., Hunt, N.C., Landers, R.J., Lewis, C.E., Royds, J.A., and Harris, A.L. (2000). Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. *J. Pathol.* *190*, 430–436.

- Lewis, C.E., and Hughes, R. (2007). Inflammation and breast cancer. Microenvironmental factors regulating macrophage function in breast tumours: hypoxia and angiopoietin-2. *Breast Cancer Res.* 9, 209.
- Lewis, C.E., and Pollard, J.W. (2006). Distinct role of macrophages in different tumor microenvironments. *Cancer Res.* 66, 605–612.
- Lin, W.W., and Karin, M. (2007). A cytokine-mediated link between innate immunity, inflammation, and cancer. *J. Clin. Invest.* 117, 1175–1183.
- Lin, E.Y., and Pollard, J.W. (2007). Tumor-associated macrophages press the angiogenic switch in breast cancer. *Cancer Res.* 67, 5064–5066.
- Lin, E.Y., Nguyen, A.V., Russell, R.G., and Pollard, J.W. (2001). Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. *J. Exp. Med.* 193, 727–740.
- Lin, E.Y., Gouon-Evans, V., Nguyen, A.V., and Pollard, J.W. (2002). The macrophage growth factor CSF-1 in mammary gland development and tumor progression. *J. Mammary Gland Biol. Neoplasia* 7, 147–162.
- Lin, E.Y., Jones, J.G., Li, P., Zhu, L., Whitney, K.D., Muller, W.J., and Pollard, J.W. (2003). Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. *Am. J. Pathol.* 163, 2113–2126.
- Lin, E.Y., Li, J.F., Gnatovskiy, L., Deng, Y., Zhu, L., Grzesik, D.A., Qian, H., Xue, X.N., and Pollard, J.W. (2006). Macrophages regulate the angiogenic switch in a mouse model of breast cancer. *Cancer Res.* 66, 11238–11246.
- Lin, E.Y., Li, J.F., Bricard, G., Wang, W., Deng, Y., Sellers, R., Porcelli, S.A., and Pollard, J.W. (2007). Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. *Mol. Oncol.* 1, 288–302.
- Lobov, I.B., Rao, S., Carroll, T.J., Vallance, J.E., Ito, M., Ondr, J.K., Kurup, S., Glass, D.A., Patel, M.S., Shu, W., et al. (2005). WNT7b mediates macrophage-induced programmed cell death in patterning of the vasculature. *Nature* 437, 417–421.
- Luo, J.L., Maeda, S., Hsu, L.C., Yagita, H., and Karin, M. (2004). Inhibition of NF- $\kappa$ B in cancer cells converts inflammation-induced tumor growth mediated by TNF $\alpha$  to TRAIL-mediated tumor regression. *Cancer Cell* 6, 297–305.
- Mantovani, A., and Sica, A. (2010). Macrophages, innate immunity and cancer: balance, tolerance, and diversity. *Curr. Opin. Immunol.*, in press.
- Mantovani, A., Allavena, P., Sica, A., and Balkwill, F. (2008). Cancer-related inflammation. *Nature* 454, 436–444.
- McAllister, S.S., Gifford, A.M., Greiner, A.L., Kelleher, S.P., Saelzler, M.P., Ince, T.A., Reinhardt, F., Harris, L.N., Hylander, B.L., Repasky, E.A., and Weinberg, R.A. (2008). Systemic endocrine instigation of indolent tumor growth requires osteopontin. *Cell* 133, 994–1005.
- Meira, L.B., Bugni, J.M., Green, S.L., Lee, C.W., Pang, B., Borenshtein, D., Rickman, B.H., Rogers, A.B., Moroski-Erkul, C.A., McFaline, J.L., et al. (2008). DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. *J. Clin. Invest.* 118, 2516–2525.
- Moghaddam, S.J., Li, H., Cho, S.N., Dishop, M.K., Wistuba, I.I., Ji, L., Kurie, J.M., Dickey, B.F., and Demayo, F.J. (2009). Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model. *Am. J. Respir. Cell Mol. Biol.* 40, 443–453.
- Mroczo, B., Groblewska, M., Wereszczyńska-Siemiakowska, U., Okulczyk, B., Kedra, B., Łaszewicz, W., Dabrowski, A., and Szmítkowski, M. (2007). Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis. *Clin. Chim. Acta* 380, 208–212.
- Murdoch, C., Muthana, M., Coffelt, S.B., and Lewis, C.E. (2008). The role of myeloid cells in the promotion of tumour angiogenesis. *Nat. Rev. Cancer* 8, 618–631.
- Naugler, W.E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A.M., and Karin, M. (2007). Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. *Science* 317, 121–124.
- Oguma, K., Oshima, H., Aoki, M., Uchio, R., Naka, K., Nakamura, S., Hirao, A., Saya, H., Taketo, M.M., and Oshima, M. (2008). Activated macrophages promote Wnt signalling through tumour necrosis factor- $\alpha$  in gastric tumour cells. *EMBO J.* 27, 1671–1681.
- Ojalvo, L.S., King, W., Cox, D., and Pollard, J.W. (2009). High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors. *Am. J. Pathol.* 174, 1048–1064.
- Ojalvo, L.S., Whittaker, C.A., Condeelis, J.S., and Pollard, J.W. (2010). Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors. *J. Immunol.* 184, 702–712.
- Oosterling, S.J., van der Bij, G.J., Meijer, G.A., Tuk, C.W., van Garderen, E., van Rooijen, N., Meijer, S., van der Sijp, J.R., Beelen, R.H., and van Egmond, M. (2005). Macrophages direct tumour histology and clinical outcome in a colon cancer model. *J. Pathol.* 207, 147–155.
- Pahler, J.C., Tazzyman, S., Erez, N., Chen, Y.Y., Murdoch, C., Nozawa, H., Lewis, C.E., and Hanahan, D. (2008). Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. *Neoplasia* 10, 329–340.
- Pang, B., Zhou, X., Yu, H., Dong, M., Taghizadeh, K., Wishnok, J.S., Tannenbaum, S.R., and Dedon, P.C. (2007). Lipid peroxidation dominates the chemistry of DNA adduct formation in a mouse model of inflammation. *Carcinogenesis* 28, 1807–1813.
- Patsialou, A., Wyckoff, J., Wang, Y., Goswami, S., Stanley, E.R., and Condeelis, J.S. (2009). Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colony-stimulating factor-1 receptor. *Cancer Res.* 69, 9498–9506.
- Pollard, J.W. (2004). Tumour-educated macrophages promote tumour progression and metastasis. *Nat. Rev. Cancer* 4, 71–78.
- Pollard, J.W. (2009). Trophic macrophages in development and disease. *Nat. Rev. Immunol.* 9, 259–270.
- Porta, C., Rimoldi, M., Raes, G., Brys, L., Ghezzi, P., Di Liberto, D., Dieli, F., Ghisletti, S., Natoli, G., De Baetselier, P., et al. (2009). Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor  $\kappa$ B. *Proc. Natl. Acad. Sci. USA* 106, 14978–14983.
- Psaila, B., and Lyden, D. (2009). The metastatic niche: adapting the foreign soil. *Nat. Rev. Cancer* 9, 285–293.
- Pucci, F., Venneri, M.A., Bizziato, D., Nonis, A., Moi, D., Sica, A., Di Serio, C., Naldini, L., and De Palma, M. (2009). A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood “resident” monocytes, and embryonic macrophages suggests common functions and developmental relationships. *Blood* 114, 901–914.
- Pukrop, T., Klemm, F., Hagemann, T., Gradl, D., Schulz, M., Siemes, S., Trümper, L., and Binder, C. (2006). Wnt 5a signaling is critical for macrophage-induced invasion of breast cancer cell lines. *Proc. Natl. Acad. Sci. USA* 103, 5454–5459.
- Qian, B., Deng, Y., Im, J.H., Muschel, R.J., Zou, Y., Li, J., Lang, R.A., and Pollard, J.W. (2009). A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. *PLoS ONE* 4, e6562.
- Robinson, B.D., Sica, G.L., Liu, Y.F., Rohan, T.E., Gertler, F.B., Condeelis, J.S., and Jones, J.G. (2009). Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination. *Clin. Cancer Res.* 15, 2433–2441.
- Robinson-Smith, T.M., Isaacsohn, I., Mercer, C.A., Zhou, M., Van Rooijen, N., Hussein, N., McFarland-Mancini, M.M., and Drew, A.F. (2007). Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. *Cancer Res.* 67, 5708–5716.
- Ryder, M., Ghossein, R.A., Ricarte-Filho, J.C., Knauf, J.A., and Fagin, J.A. (2008). Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. *Endocr. Relat. Cancer* 15, 1069–1074.

- Saccani, A., Schioppa, T., Porta, C., Biswas, S.K., Nebuloni, M., Vago, L., Bottazzi, B., Colombo, M.P., Mantovani, A., and Sica, A. (2006). p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. *Cancer Res.* 66, 11432–11440.
- Saji, H., Koike, M., Yamori, T., Saji, S., Seiki, M., Matsushima, K., and Toi, M. (2001). Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. *Cancer* 92, 1085–1091.
- Sangaletti, S., Di Carlo, E., Gariboldi, S., Miotti, S., Cappetti, B., Parenza, M., Rumio, C., Brekken, R.A., Chiodoni, C., and Colombo, M.P. (2008). Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis. *Cancer Res.* 68, 9050–9059.
- Sapi, E., and Kacinski, B.M. (1999). The role of CSF-1 in normal and neoplastic breast physiology. *Proc. Soc. Exp. Biol. Med.* 220, 1–8.
- Scholl, S.M., Pallud, C., Beuvon, F., Hacene, K., Stanley, E.R., Rohrschneider, L.R., Tang, R., Pouillart, P., and Lidereau, R. (1994). Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. *J. Natl. Cancer Inst.* 86, 120–126.
- Sharma, M., Beck, A.H., Webster, J.A., Espinosa, I., Montgomery, K., Varma, S., van de Rijn, M., Jensen, K.C., and West, R.B. (2009). Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ. *Breast Cancer Res. Treat.* Published online December 1, 2009. 10.1007/s10549-009-0654-0.
- Smith, H.O., Anderson, P.S., Kuo, D.Y., Goldberg, G.L., DeVictoria, C.L., Boocock, C.A., Jones, J.G., Runowicz, C.D., Stanley, E.R., and Pollard, J.W. (1995). The role of colony-stimulating factor 1 and its receptor in the etiology of endometrial adenocarcinoma. *Clin. Cancer Res.* 1, 313–325.
- Stockmann, C., Doedens, A., Weidemann, A., Zhang, N., Takeda, N., Greenberg, J.I., Cheresch, D.A., and Johnson, R.S. (2008). Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. *Nature* 456, 814–818.
- Suzuki, H., Forrest, A.R., van Nimwegen, E., Daub, C.O., Balwiercz, P.J., Irvine, K.M., Lassmann, T., Ravasi, T., Hasegawa, Y., de Hoon, M.J., et al. FANTOM Consortium; Riken Omics Science Center. (2009). The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line. *Nat. Genet.* 41, 553–562.
- Swann, J.B., Vesely, M.D., Silva, A., Sharkey, J., Akira, S., Schreiber, R.D., and Smyth, M.J. (2008). Demonstration of inflammation-induced cancer and cancer immunoeediting during primary tumorigenesis. *Proc. Natl. Acad. Sci. USA* 105, 652–656.
- Tanaka, K., Kurebayashi, J., Sohda, M., Nomura, T., Prabhakar, U., Yan, L., and Sonoo, H. (2009). The expression of monocyte chemoattractant protein-1 in papillary thyroid carcinoma is correlated with lymph node metastasis and tumor recurrence. *Thyroid* 19, 21–25.
- Torroella-Kouri, M., Silvera, R., Rodriguez, D., Caso, R., Shatry, A., Opiela, S., Ilkovitch, D., Schwendener, R.A., Iragavarapu-Charyulu, V., Cardentey, Y., et al. (2009). Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated. *Cancer Res.* 69, 4800–4809.
- Varney, M.L., Johansson, S.L., and Singh, R.K. (2005). Tumour-associated macrophage infiltration, neovascularization and aggressiveness in malignant melanoma: role of monocyte chemoattractant protein-1 and vascular endothelial growth factor-A. *Melanoma Res.* 15, 417–425.
- Vasijjeva, O., Papazoglou, A., Krüger, A., Brodoefel, H., Korovin, M., Deussing, J., Augustin, N., Nielsen, B.S., Almholt, K., Bogoyo, M., et al. (2006). Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. *Cancer Res.* 66, 5242–5250.
- Wang, S., Yuan, Y., Liao, L., Kuang, S.Q., Tien, J.C., O'Malley, B.W., and Xu, J. (2009). Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis without affecting primary tumor formation. *Proc. Natl. Acad. Sci. USA* 106, 151–156.
- Wyckoff, J., Wang, W., Lin, E.Y., Wang, Y., Pixley, F., Stanley, E.R., Graf, T., Pollard, J.W., Segall, J., and Condeelis, J. (2004). A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. *Cancer Res.* 64, 7022–7029.
- Wyckoff, J.B., Wang, Y., Lin, E.Y., Li, J.F., Goswami, S., Stanley, E.R., Segall, J.E., Pollard, J.W., and Condeelis, J. (2007). Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. *Cancer Res.* 67, 2649–2656.
- Yoshidome, H., Kohno, H., Shida, T., Kimura, F., Shimizu, H., Ohtsuka, M., Nakatani, Y., and Miyazaki, M. (2009). Significance of monocyte chemoattractant protein-1 in angiogenesis and survival in colorectal liver metastases. *Int. J. Oncol.* 34, 923–930.
- Yu, H., Kortylewski, M., and Pardoll, D. (2007). Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. *Nat. Rev. Immunol.* 7, 41–51.
- Zabuawala, T., Taffany, D.A., Sharma, S.M., Merchant, A., Adair, B., Srinivasan, R., Rosol, T.J., Fernandez, S., Huang, K., Leone, G., and Ostrowski, M.C. (2010). An ets2-driven transcriptional program in tumor-associated macrophages promotes tumor metastasis. *Cancer Res.* 70, 1323–1333.
- Zeisberger, S.M., Odermatt, B., Marty, C., Zehnder-Fjällman, A.H., Ballmer-Hofer, K., and Schwendener, R.A. (2006). Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective anti-angiogenic therapy approach. *Br. J. Cancer* 95, 272–281.
- Zhu, P., Baek, S.H., Bourk, E.M., Ohgi, K.A., Garcia-Bassets, I., Sanjo, H., Akira, S., Kotol, P.F., Glass, C.K., Rosenfeld, M.G., and Rose, D.W. (2006). Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. *Cell* 124, 615–629.
- Zhu, X.D., Zhang, J.B., Zhuang, P.Y., Zhu, H.G., Zhang, W., Xiong, Y.Q., Wu, W.Z., Wang, L., Tang, Z.Y., and Sun, H.C. (2008). High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. *J. Clin. Oncol.* 26, 2707–2716.
- Zijlmans, H.J., Fleuren, G.J., Baelde, H.J., Eilers, P.H., Kenter, G.G., and Gorter, A. (2006). The absence of CCL2 expression in cervical carcinoma is associated with increased survival and loss of heterozygosity at 17q11.2. *J. Pathol.* 208, 507–517.
- Zumsteg, A., and Christofori, G. (2009). Corrupt policemen: inflammatory cells promote tumor angiogenesis. *Curr. Opin. Oncol.* 21, 60–70.

#### Note Added in Proof

During the production of this review, data reinforcing the role of macrophages in the progression of Hodgkin's lymphoma (Steidl, C., Lee, T., Shah, S.P., Farinha, P., Han, G., Nayar, T., Delaney, A., Jones, S.J., Iqbal, J., Weisenburger, D.D. et al. [2010]. *N. Engl. J. Med.* 362, 875–885), in angiogenesis (Priceman, S.J., Sung, J.L., Shaposhnik, Z., Burton, J.B., Torres-Collado, A.X., Moughon, D.L., Johnson, M., Lusic, A.J., Cohen, D.A., Iruela-Arispe, M.L., and Wu, L. [2010]. *Blood* 115, 1461–1471), and in tumor growth (Loges, S., Schmidt, T., Tjwa, M., van Geyte, K., Lievens, D., Lutgens, E., Vanhoutte, D., Borgel, D., Plaisance, S., Hoylaerts, M. et al. [2010]. *Blood* 115, 2264–2273) were published.